Merck’s Tredaptive Raises Risk of Muscle Pain in Study
This article is for subscribers only.
Merck & Co.’s cholesterol therapy Tredaptive, which the company stopped selling this year because it was ineffective and possibly harmful, raised rates of muscle pain and weakness in patients, a study found.
Muscle pain and weakness were found to be most common in Chinese patients, researchers said, with rates four times higher than those on placebo or of Europeans in the study of 25,673 patients published today in the European Heart Journal.